Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Interventional × Malignant Disease × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2863 Carcinoma, Non-Small-Cell Lung 2400 Breast Neoplasms 2053 Colorectal Neoplasms 1223 Neoplasm Metastasis 1216 Prostatic Neoplasms 1062 Melanoma 969 Multiple Myeloma 950 Ovarian Neoplasms 893 Recurrence 842 Leukemia, Myeloid, Acute 803 Lung Neoplasms 755 Pancreatic Neoplasms 743 Lymphoma, Non-Hodgkin 721 Lymphoma 659 Stomach Neoplasms 617 Carcinoma, Hepatocellular 561 Carcinoma, Renal Cell 540 Squamous Cell Carcinoma of Head and Neck 523 Leukemia, Lymphocytic, Chronic, B-Cell 490 Lymphoma, Follicular 461 Head and Neck Neoplasms 448 Glioblastoma 433 Advanced Solid Tumors 419 Triple Negative Breast Neoplasms 403 Small Cell Lung Carcinoma 402 Lymphoma, Large B-Cell, Diffuse 396 Leukemia 391 Uterine Cervical Neoplasms 368 Advanced Solid Tumor 348

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡